Hoogar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 18 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.40 Cr
- Revenue Growth -43.01%
- Profit Growth -49.72%
- Ebitda -27.30%
- Net Worth -268.05%
- Total Assets 9.00%
About Hoogar Pharmaceuticals
Hoogar Pharmaceuticals Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 July 2006 and has a history of 18 years and seven months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.40 Cr.
Jyothi Hoogar and Naveen Hoogar serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52311KA2006PTC039922
- Company No.
039922
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 2006
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Hoogar Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyothi Hoogar  | Director | 11-Jul-2006 | Current |
| Naveen Hoogar | Director | 12-Aug-2021 | Current |
Financial Performance of Hoogar Pharmaceuticals.
Hoogar Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 43.01% decrease. The company also saw a substantial fall in profitability, with a 49.72% decrease in profit. The company's net worth observed a substantial decline by a decrease of 268.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hoogar Pharmaceuticals?
In 2017, Hoogar Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹14.00 M
₹0
Charges Breakdown by Lending Institutions
- Karnataka State Financial Corporation : 1.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Oct 2019 | Karnataka State Financial Corporation | ₹1.00 Cr | Open |
| 02 May 2011 | Karnataka State Financial Corporation | ₹4.00 M | Open |
How Many Employees Work at Hoogar Pharmaceuticals?
Unlock and access historical data on people associated with Hoogar Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hoogar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hoogar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
